Quantification of blood Gd-DTPA levels : implications on dosing dGEMRIC

Delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC) is a novel technique that allows early diagnosis of osteoarthritis (OA). Under the current protocol, subjects are injected 0.2mmol of an MRI contrast agent (Gd-DTPA 2, Berlex Imaging, Wayne, NJ) per kilogram of body weight. Because the distribution volume of Gd-DTPA - is affected by body composition, subjects with high Body Mass Index (BMI) may effectively be dosed higher compared to low BMI subjects. In this study, 0.2mmol of Gd-DTPA2- per kilogram of body weight was injected into 17 subjects with varying BMI. Their blood Gd-DTPA - levels were measured at 15, 30, 45, 60, 90, and 120 minutes post-injection. Although there was a wide scatter in Gd-DTPA2- levels both across the subjects and within subjects of similar BMI, results indicated a positive relationship between blood Gd-DTPA2- levels and BMI. It was determined that this effect could lead to over-pronounced OA severity for high BMI subjects. However, further experiments are needed to understand the scatter to better quantify the effect BMI could have on dGEMRIC.

Department dc:contributor.department

Massachusetts Institute of Technology. Dept. of Electrical Engineering and Computer Science.

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2005

Author dc:creator

• Hori, Marisa

Advisor dc:contributor.advisor

• Deborah Burstein.

• Electrical Engineering and Computer Science.

Statement dc:rights

• M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/1721.1/36786

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/36786